Home Cart 0 Sign in  
X

[ CAS No. 40545-33-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 40545-33-3
Chemical Structure| 40545-33-3
Chemical Structure| 40545-33-3
Structure of 40545-33-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 40545-33-3 ]

Related Doc. of [ 40545-33-3 ]

Alternatived Products of [ 40545-33-3 ]

Product Details of [ 40545-33-3 ]

CAS No. :40545-33-3 MDL No. :MFCD03428521
Formula : C8H10N2O Boiling Point : -
Linear Structure Formula :- InChI Key :LLSGVPKOCZZLTF-UHFFFAOYSA-N
M.W : 150.18 Pubchem ID :10329436
Synonyms :

Calculated chemistry of [ 40545-33-3 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 2.0
Molar Refractivity : 43.91
TPSA : 69.11 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.42 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.96
Log Po/w (XLOGP3) : 1.12
Log Po/w (WLOGP) : 0.68
Log Po/w (MLOGP) : 0.91
Log Po/w (SILICOS-IT) : 0.71
Consensus Log Po/w : 0.88

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.81
Solubility : 2.3 mg/ml ; 0.0153 mol/l
Class : Very soluble
Log S (Ali) : -2.16
Solubility : 1.03 mg/ml ; 0.00684 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.0
Solubility : 1.51 mg/ml ; 0.0101 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 40545-33-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 40545-33-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 40545-33-3 ]
  • Downstream synthetic route of [ 40545-33-3 ]

[ 40545-33-3 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 40545-33-3 ]
  • [ 149-73-5 ]
  • [ 19181-53-4 ]
YieldReaction ConditionsOperation in experiment
81% With hydrogenchloride In water at 0 - 20℃; for 2 h; Concentrated hydrochloric acid (4.16 mL, 49.9 mmol) was added to a mixture of commercially available 2-amino-5-methylbenzamide 14 (5.00 g, 33.3 mmol) and trimethyl orthoformate (51.0 mL, 466 mmol) at 0 °C and the mixture was stirred at room temperature for 2 h. After the mixture was concentrated under reduced pressure, the residue was diluted with water and neutralized with 2 M aqueous sodium hydroxide solution. The precipitated solid was collected and washed with H2O, methanol and diethyl ether to give 15 as a white powder (4.33 g, 81percent). 1H NMR (300 MHz, DMSO-d6) d 2.44 (3H, s), 7.57 (1H, d, J = 8.4 Hz), 7.62–7.66 (1H, m), 7.91–7.93 (1H, m), 8.03 (1H, s), 12.2 (1H, bs).
Reference: [1] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 19, p. 5487 - 5505
[2] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 4, p. 545 - 548
[3] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 3, p. 383 - 391
  • 2
  • [ 67-56-1 ]
  • [ 40545-33-3 ]
  • [ 19181-53-4 ]
YieldReaction ConditionsOperation in experiment
90% at 130℃; for 2 h; Inert atmosphere; Microwave irradiation 2-amino-5-methylbenzamide (75 mg, 0.5 mmol), [Cp * Ir (2,2'-bpyO) (H2O)](5.4 mg, 0.005 mmol, 1 molpercent),Cesium carbonate (49 mg, 0.15 mmol, 0.3 equiv.) And methanol (0.5 ml) were sequentially added to a dried 5 mL microwave reaction tube.Microwave tube nitrogen protection,Placed in a single mode pressure microwave synthesizer (Discover CEM,USA). After the reaction mixture was reacted at 130 ° C for 2 hours,Cool to room temperature. Rotary evaporation to remove the solvent,Then, column chromatography (developing solvent: petroleum ether / ethyl acetate)The pure target compound was obtained in a yield of 90percent
Reference: [1] Organic Letters, 2016, vol. 18, # 11, p. 2580 - 2583
[2] Patent: CN107337646, 2017, A, . Location in patent: Paragraph 0035; 0036; 0037; 0038
  • 3
  • [ 40545-33-3 ]
  • [ 58421-79-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 3, p. 383 - 391
[2] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 4, p. 545 - 548
  • 4
  • [ 40545-33-3 ]
  • [ 123-54-6 ]
  • [ 18731-19-6 ]
Reference: [1] Journal of Organic Chemistry, 2015, vol. 80, # 19, p. 9392 - 9400
  • 5
  • [ 4315-12-2 ]
  • [ 40545-33-3 ]
YieldReaction ConditionsOperation in experiment
99% With hydrogen In methanol at 20℃; for 12 h; Step 2
To a solution of 5-methyl-2-nitrobenzamide (15.0 g, 83.3 mmol) in methanol (300 mL) was added 10percent palladium carbon (2.50 g), and the mixture was stirred at room temperature for 12 hr under hydrogen atmosphere (1 atm).
The insoluble material was filtered off, and the filtrate was concentrated to give 2-amino-5-methylbenzamide as a white powder (12.4 g, 99percent).
99% With palladium 10% on activated carbon; hydrogen In methanol at 10 - 35℃; for 12 h; Step 2
To a solution of 5-methyl-2-nitrobenzamide (15.0 g, 83.3 mmol) in MeOH (300 mL) was added 10percent Pd-C (2.50 g), and the mixture was stirred under a hydrogen atmosphere (1 atm) at room temperature for 12 hrs.
Insoluble material was filtered off and the filtrate was concentrated to give 2-amino-5-methylbenzamide as a white powder (12.4 g, 99percent).
96% With H2 In methanol A solution of 13 (31.5 g, 0.175 mol) in MeOH (250 mL) was shaken With 5percent Pd-C (0.5 g) under 3 atm. of H2 for 24 h in a Parr apparatus.
A solid formed after the initial heat of reaction subsided.
The mixture was heated to boiling to redissolve the product, and was filtered while hot.
The filtrate was evaporated under reduced pressure and the residue dried at 90° C. for 1 h (caution: some sublimation may occur) to obtain 2-amino-5-methylbenzamide (14) as a white solid (25.3 g, 96percent); mp 173°-175° C. [lit. (Findeklee) mp 179° C.]; 1 H-NMR (CDCl3) δ6.60 (d, 1H, J=8 Hz, C3 -H).
Reference: [1] Patent: EP1953148, 2008, A1, . Location in patent: Page/Page column 130
[2] Patent: US2015/329556, 2015, A1, . Location in patent: Paragraph 1532
[3] Journal of Medicinal Chemistry, 1992, vol. 35, # 14, p. 2626 - 2630
[4] Patent: US5234925, 1993, A,
[5] European Journal of Medicinal Chemistry, 2011, vol. 46, # 7, p. 2786 - 2796
[6] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 427 - 435
[7] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 19, p. 6305 - 6316
[8] European Journal of Medicinal Chemistry, 2017, vol. 132, p. 262 - 273
  • 6
  • [ 2941-78-8 ]
  • [ 40545-33-3 ]
YieldReaction ConditionsOperation in experiment
74%
Stage #1: With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide for 3 h; Inert atmosphere
Stage #2: With ammonium hydroxide In water; N,N-dimethyl-formamide for 16 h;
Compound 23 (3.00 g , 19.78 mmol) was treated withEDC.HCl (4.17 g, 21.8 mmol) and HOBt (3.33 g, 21.8 mmol) in dry DMF (100 mL) under Arfor 3 h, after which aq. NH3 (35percent, 20 mL) was added and the mixture was stirred for 16 h.The evaporation residue, in EtOAc, was and washed twice with water and with brine. Dryingand evaporation gave 26 as an off-white solid (2.21 g, 74percent): mp 180-182°C (lit.S13 mp 175-177°C); 1H NMR ((CD3)2SO) 2.20 (3 H, s, Me), 6.35 (2 H, brs, NH2), 6.64 (1 H, d, J = 8.3Hz, 3-H), 7.01 (2 H, m, 4-H + CONHH), 7.40 (1 H, d, J = 1.2 Hz, 6-H), 7.68 (1 H, s,CONHH); 13C NMR ((CD3)2SO) (HSQC / HMBC) 19.98 (Me), 113.78 (1-C), 116.52 (3-C),122.68 (5-C), 128.64 (6-C), 132.67 (4-C), 147.84 (2-C), 171.27 (C=O).
70% With N-hydroxybenzotriazole ammonium salt; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 1 h; To a stirred solution of 2-amino-5-methyl-benzoic acid (100 mg, 0.66 mmol) in THF (2 mL),EDC.HCl (189 mg, 0.99 mmol), HOBt·NH3 (149 mg, 0.99 mmol) and DIPEA (0.35 mL, 1.99mmol) were added at RT and stirred for 1 h (TLC indicated complete conversion of thestarting material). The reaction mixture was diluted with EtOAc (1 x 50 mL), washed withwater (1 x 20 mL) and brine solution (1 x 20 mL). The organic layer was separated, dried over Na2S04, volatiles were evaporated under reduced pressure to give the crude residuewhich was purified by Combiflash Rf 200 Teledyne ISCO (100percent EtOAc, 12 gm cartridge) toafford 2-amino-5-methyl-benzamide (70 mg, 70percent) as a white solid.LCMS (ESI+): m/z: 151.13 [M+Ht.
Reference: [1] European Journal of Medicinal Chemistry, 2016, vol. 118, p. 316 - 327
[2] Journal of Organic Chemistry, 2017, vol. 82, # 14, p. 7165 - 7175
[3] Patent: WO2018/125961, 2018, A1, . Location in patent: Page/Page column 51; 52
[4] Organic Letters, 2013, vol. 15, # 2, p. 378 - 381
[5] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 3, p. 383 - 391
[6] Journal of Agricultural and Food Chemistry, 2015, vol. 63, # 31, p. 6883 - 6889
  • 7
  • [ 5925-93-9 ]
  • [ 40545-33-3 ]
YieldReaction ConditionsOperation in experiment
90% With water; potassium carbonate In water at 150℃; for 0.5 h; Microwave irradiation General procedure: Adapted from a literature procedure,1 the appropriate organonitrile (1.0 eq.) and K2CO3(0.2eq.)wereaddedtoamicrowavetubewithastir-barwithdeionizedwater(8.5mLpermmolsubstrate).Afterirradiationundermicrowaveat150°Cfor30minutes,thereactionmixturewascooled,extractedwithEtOAc(320mL),thecombinedphasesdriedoverMgSO4andexcesssolventremovedinvacuo.TheresiduewaspurifiedbyFCC,ifrequired,togivethetitlecompound.
Reference: [1] Synthesis (Germany), 2017, vol. 49, # 1, p. 135 - 144
  • 8
  • [ 79-37-8 ]
  • [ 3113-72-2 ]
  • [ 40545-33-3 ]
YieldReaction ConditionsOperation in experiment
89% With ammonia In tetrahydrofuran; methanol; N,N-dimethyl-formamide 28a
2-Amino-5-methylbenzamide
To a stirred solution of 5-methyl-2-nitrobenzoic acid (25.4 g) in THF (150 ml) was added oxalyl chloride (13.5 ml) and DMF (0.1 ml) dropwise and the mixture was stirred at room temperature for 14 hours and concentrated to dryness.
To an ice-cooled, stirred 25percent aqueous solution of ammonia (150 ml) was added the resulting acid chloride dropwise and the mixture was stirred at the same temperature for 1 hour.
The white precipitates were collected by filtration, washed with water, and dried in vacuo.
A suspension of the white precipitates and 10percent Pd/C (2.4 g) in a mixture of THF (200 ml) and methanol (150 ml) was stirred under hydrogen atmosphere at room temperature for 4 hours.
After removal of insoluble materials by filtration, the filtrate was concentrated to dryness.
Recrystallization of the resultant crystalline residue from ethyl acetate-hexane afforded colorless crystals (18.7 g, 89percent), m.p. 178°-180° C.
1 H-NMR(200 MHz,DMSO-d6) δ: 2.15(3H,s), 6.30(2H,brs), 6.58(1H,d), 6.95(1H,dd), 6.97(1H,br), 7.34(1H,d), 7.64(1H,br) IR(KBr) cm-1: 3380, 3200, 1645, 1580, 1552
Reference: [1] Patent: US5389641, 1995, A,
  • 9
  • [ 3113-72-2 ]
  • [ 40545-33-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 14, p. 2626 - 2630
[2] European Journal of Medicinal Chemistry, 2011, vol. 46, # 7, p. 2786 - 2796
[3] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 427 - 435
[4] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 19, p. 6305 - 6316
[5] European Journal of Medicinal Chemistry, 2017, vol. 132, p. 262 - 273
[6] Patent: US2015/329556, 2015, A1,
  • 10
  • [ 2941-78-8 ]
  • [ 530-62-1 ]
  • [ 40545-33-3 ]
Reference: [1] Patent: US5001157, 1991, A,
  • 11
  • [ 4692-99-3 ]
  • [ 40545-33-3 ]
Reference: [1] Journal of Chemical Research, Miniprint, 1987, # 7, p. 1839 - 1868
[2] Journal of Agricultural and Food Chemistry, 2015, vol. 63, # 31, p. 6883 - 6889
  • 12
  • [ 38818-49-4 ]
  • [ 40545-33-3 ]
Reference: [1] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 427 - 435
[2] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 19, p. 6305 - 6316
[3] European Journal of Medicinal Chemistry, 2017, vol. 132, p. 262 - 273
[4] Patent: US2015/329556, 2015, A1,
  • 13
  • [ 64113-86-6 ]
  • [ 40545-33-3 ]
Reference: [1] Chemische Berichte, 1905, vol. 38, p. 3555
  • 14
  • [ 620-22-4 ]
  • [ 40545-33-3 ]
Reference: [1] Chemische Berichte, 1905, vol. 38, p. 3555
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 40545-33-3 ]

Aryls

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.98

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.98

Chemical Structure| 711007-44-2

[ 711007-44-2 ]

2,3-Diaminobenzamide

Similarity: 0.93

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1904-58-1

[ 1904-58-1 ]

2-Aminobenzhydrazide

Similarity: 0.89

Amides

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.98

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.98

Chemical Structure| 711007-44-2

[ 711007-44-2 ]

2,3-Diaminobenzamide

Similarity: 0.93

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1904-58-1

[ 1904-58-1 ]

2-Aminobenzhydrazide

Similarity: 0.89

Amines

Chemical Structure| 39549-79-6

[ 39549-79-6 ]

2-Amino-4-methylbenzamide

Similarity: 0.98

Chemical Structure| 1885-32-1

[ 1885-32-1 ]

2-Amino-3-methylbenzamide

Similarity: 0.98

Chemical Structure| 711007-44-2

[ 711007-44-2 ]

2,3-Diaminobenzamide

Similarity: 0.93

Chemical Structure| 2835-68-9

[ 2835-68-9 ]

4-Aminobenzamide

Similarity: 0.93

Chemical Structure| 1904-58-1

[ 1904-58-1 ]

2-Aminobenzhydrazide

Similarity: 0.89